GlassScriptPhysician profile
Christopher John Alvarado
NPI 1073772968
$35,388.30
in general payments reported to CMS, 2019-2025
54 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,700 · 2020: $14K · 2021: $1,304 · 2022: $2,132 · 2023: $1,505 · 2024: $1,269 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,313 · Food and Beverage: $3,867 · Travel and Lodging: $361 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,312.50 |
| Food and Beverage | $3,866.55 |
| Travel and Lodging | $361.19 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17,154.21 | 2019-2024 | |
| Exact Sciences Corporation | $10,235.81 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $1,136.51 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,060.61 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $984.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $650.45 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $527.96 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.46 | 2019-2024 | Jardiance |
| Nestle Healthcare Nutrition INC. | $279.83 | 2020-2023 | |
| Glaxosmithkline, LLC. | $253.17 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $236.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.75 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $207.14 | 2019-2025 | Airduo Digihaler, Austedo Xr |
| Vanda Pharmaceuticals INC. | $183.26 | 2022 | |
| Allergan, INC. | $147.06 | 2019-2020 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Alvarado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.